Cellebrite DI (NASDAQ:CLBT) CRO Sells $141,196.88 in Stock

Cellebrite DI Ltd. (NASDAQ:CLBT) CRO Marcus Jewell sold 12,562 shares of the firm’s stock in a transaction that occurred on Friday, August 21st. The shares were sold at an average price of $11.24, for a total value of $141,196.88. Following the completion of the sale, the executive owned 427,128 shares in the company, valued at approximately $4,800,918.72. This represents a 2.86% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Marcus Jewell also recently made the following trade(s):

• On Wednesday, August 12th, Marcus Jewell sold 411 shares of Cellebrite DI stock. The shares were sold at an average price of $16.07, for a total value of $6,604.77.

Cellebrite DI Stock Performance

Shares of CLBT stock opened at $11.62 on Thursday. Cellebrite DI Ltd. has a 1 year low of $9.58 and a 1 year high of $19.98. The firm has a market capitalization of $2.90 billion, a PE ratio of 52.82, a price-to-earnings-growth ratio of 1.73 and a beta of 1.18. The stock has a fifty day moving average of $14.19 and a two-hundred day moving average of $13.80.

Key Stories Impacting Cellebrite DI

Here are the key news stories impacting Cellebrite DI this week:

• Positive Sentiment: Cellebrite launched the Portable Tactical Extraction Kit (C-TEK), a field-deployable digital-forensics solution for armed forces. The kit enables forward-deployed teams to rapidly triage data from phones, SIM cards, drones and portable media, expanding Cellebrite’s addressable market in defense and battlefield intelligence. C-TEK launch announcement
• Positive Sentiment: The announcement reinforces Cellebrite’s positioning as a provider of AI-enabled digital investigation and intelligence tools for governments, law enforcement and enterprises. Any adoption by military customers could support longer-term revenue growth, although the release did not disclose contracts or financial targets.
• Neutral Sentiment: Analyst opinion remains broadly constructive, with five Buy ratings and one Sell rating and a consensus price target of $16.70. However, JPMorgan, DA Davidson, Lake Street and Needham recently lowered their targets, signaling more cautious expectations after the stock’s decline.
• Neutral Sentiment: Reported short interest was zero shares, producing no meaningful short-interest signal. The data also contained an anomalous percentage-change figure, limiting its usefulness for assessing near-term trading pressure.
• Negative Sentiment: Kaplan Fox & Kilsheimer announced an investigation into potential securities-law violations involving Cellebrite. The announcement does not establish wrongdoing, but it adds legal, reputational and potential litigation risk that could weigh on investor sentiment. Kaplan Fox investigation
• Negative Sentiment: Chief Marketing Officer David Nicholas Gee sold 4,323 shares for approximately $49,100, following a sale of 2,198 shares worth about $24,700 several days earlier. The latest transaction was made under a pre-arranged Rule 10b5-1 plan and leaves him with a substantial holding, but repeated executive sales may still pressure sentiment. Insider sale filing

Wall Street Analyst Weigh In

CLBT has been the topic of a number of recent analyst reports. Lake Street Capital dropped their price target on shares of Cellebrite DI from $21.00 to $15.00 and set a “buy” rating on the stock in a research report on Friday, August 14th. Weiss Ratings cut shares of Cellebrite DI from a “hold (c-)” rating to a “sell (d+)” rating in a report on Thursday, August 13th. Needham & Company LLC lowered their price objective on shares of Cellebrite DI from $15.00 to $12.50 and set a “buy” rating on the stock in a research note on Friday, August 14th. DA Davidson dropped their target price on Cellebrite DI from $22.00 to $15.00 and set a “buy” rating on the stock in a report on Friday, August 14th. Finally, JPMorgan Chase & Co. cut their target price on Cellebrite DI from $20.00 to $16.00 and set an “overweight” rating for the company in a research report on Friday, August 14th. Five analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $16.70.

Institutional Trading of Cellebrite DI

Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. Towarzystwo Funduszy Inwestycyjnych PZU SA increased its holdings in shares of Cellebrite DI by 81.0% in the fourth quarter. Towarzystwo Funduszy Inwestycyjnych PZU SA now owns 1,900 shares of the company’s stock valued at $34,000 after buying an additional 850 shares in the last quarter. Advisory Services Network LLC purchased a new stake in shares of Cellebrite DI during the third quarter valued at $40,000. CWM LLC boosted its position in shares of Cellebrite DI by 57.0% in the 4th quarter. CWM LLC now owns 2,449 shares of the company’s stock valued at $44,000 after purchasing an additional 889 shares during the period. Elevation Wealth Partners LLC acquired a new position in shares of Cellebrite DI in the 2nd quarter valued at $44,000. Finally, Vestcor Inc purchased a new position in Cellebrite DI in the 3rd quarter worth about $70,000. 45.88% of the stock is owned by institutional investors and hedge funds.

About Cellebrite DI

Cellebrite DI is a global provider of digital intelligence and forensics solutions that enable law enforcement agencies, government bodies and enterprises to extract, analyze and act on data from mobile devices, cloud services and digital sources. The company’s technology is designed to accelerate investigations, support evidence-based decision-making and enhance security operations by delivering actionable intelligence in a secure, scalable platform.

The company’s flagship offerings include the Universal Forensic Extraction Device (UFED) series for data acquisition and decoding, Physical Analyzer for advanced data parsing and visualization, and Pathfinder for case-driven investigation workflows.